title: Fluoxetine decreases concentrations of 3 alpha, 5 alpha-tetrahydrodeoxycorticosterone (THDOC) in major depression.
abstract: There is evidence for a differential alteration in the concentrations of 3 alpha-reduced neuroactive steroids in major depression. Because it has been suggested that fluoxetine may shift the activity of the 3 alpha-hydroxysteroid oxidoreductase towards the reductive direction, treatment of major depression may be accompanied by a further increase in plasma 3 alpha, 5 alpha-tetrahydrodeoxycorticosterone (THDOC) concentration. We studied eight male depressed patients before and after treatment with fluoxetine and compared them to healthy age-matched control subjects. Blood samples were quantified for 3 alpha, 5 alpha-tetrahydroprogesterone, 3 alpha,5 beta-tetrahydroprogesterone (THP) and THDOC by means of a highly sensitive combined gas chromatography/mass spectrometry analysis. Compared to control subjects, concentrations of THDOC were higher in depressed patients and decreased after fluoxetine treatment. In contrast, THP concentrations were lower in depressed patients and increased after fluoxetine treatment. Our results give further evidence for a disequilibrium of 3 alpha-reduced neuroactive steroids in major depression, which is normalized by treatment with fluoxetine.
authors.affiliation: Max Planck Institute of Psychiatry, Kraepelinstrasse 10, 80804, Munich, Germany. stroehle@mpipsykl.mpg.de
authors.forename: A
authors.initials: A
authors.lastname: Ströhle
authors.forename: A
authors.initials: A
authors.lastname: Pasini
authors.forename: E
authors.initials: E
authors.lastname: Romeo
authors.forename: B
authors.initials: B
authors.lastname: Hermann
authors.forename: G
authors.initials: G
authors.lastname: Spalletta
authors.forename: F
authors.initials: F
authors.lastname: di Michele
authors.forename: F
authors.initials: F
authors.lastname: Holsboer
authors.forename: R
authors.initials: R
authors.lastname: Rupprecht
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology* / Q000627:therapeutic use; D016022:Case-Control Studies; D003865:Major Depressive Disorder / Q000097:blood* / Q000188:drug therapy*; D003900:Desoxycorticosterone / Q000031:analogs & derivatives* / Q000097:blood; D005473:Fluoxetine / Q000494:pharmacology* / Q000627:therapeutic use; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D011569:Psychiatric Status Rating Scales; D012074:Remission Induction; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003900:Desoxycorticosterone; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors; C009413:tetrahydrodeoxycorticosterone